Decide at what price you'd be comfortable buying and we'll help you stay ready.
Molecular Partners is a Swiss biotechnology company that develops DARPin drugs, which are lab-made protein binders designed to attach tightly to disease targets. Its work centers on turning these engineered molecules into medicines for cancer and other serious diseases, with a heavy focus on treatments that can be given as targeted therapies rather than broad chemical drugs.
The company does not sell consumer products. It makes money mainly by advancing its drug candidates through research, clinical development, and partnerships with larger pharmaceutical companies. In this model, Molecular Partners can receive research funding, milestone payments, and royalties if partnered programs succeed, while also trying to build value in its own pipeline of experimental medicines.
What makes the business different is the DARPin technology itself. Instead of using traditional antibodies or small-molecule drugs, Molecular Partners builds custom proteins that can be tuned for specific targets and combinations of targets. That gives it a place as a technology-driven drug developer and a potential partner for companies looking for highly selective biologic therapies.
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more